Recent Press Releases

Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration to Express the Storie

2011 REYATAZ® (atazanavir sulfate) “Fight HIV Your Way” Contest Call for Entries Begins on December 1, 2010 PRINCETON, N.J. and NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY)

Apricus Biosciences Appoints Manufacturer for Vitaros®, Its Newly Approved Drug to Treat Erectile Dysfunction in Canada

SAN DIEGO--(BUSINESS WIRE)-- Apricus Biosciences, Inc. (“Apricus Bio”) (NASDAQ: APRI), announced today that it has appointed a manufacturer for Vitaros®, its new treatment for erectile dysfunction

Congress Called Upon to Eliminate Restriction on Use of Flexible Spending Accounts for Over-the-Counter Medications

WASHINGTON, Dec. 1, 2010 /PRNewswire-USNewswire/ -- Unless Congress takes action during the upcoming lame duck session, Americans will be prohibited from using their pre-tax flexible spending account

SDI REPORTS: GLAXOSMITHKLINE SALES FORCE NO. 1 WITH PRIMARY CARE PHYSICIANS

SDI REPORTS: GLAXOSMITHKLINE SALES FORCE NO. 1 WITH PRIMARY CARE PHYSICIANSMaker of Advair Diskus, Lovaza and Avodart Jumps to First from Third in 2009PLYMOUTH MEETING, Pa. - Nov. 30, 2010 -

Novartis Pharmaceuticals Corporation (NVS) to Cut 1,400 US Jobs

Novartis Pharmaceuticals Corporation (NVS) to Cut 1,400 US Jobs East Hanover, N.J., November 30, 2010 - Novartis Pharmaceuticals Corporation (NPC) announced today that it is restructuring its General

Although Enbrel Will Remain Surveyed Dermatologists' Most-Prescribed First-Line Biologic for Psoriasis, It Will Lose Market Shar

The Current Reimbursement Environment Creates a Significant Barrier for Agents Targeting the TNF-Refractory Population, According to a New Report from Decision ResourcesBURLINGTON, Mass., Dec. 1,

China's Type 2 Diabetes Market Will Grow to $2.5 Billion in 2014

Rising Sales from Newly Launched Western-branded Products Will Offset Generic Erosion from Older Agents, According to a New Report from Decision ResourcesBURLINGTON, Mass., Dec. 1, 2010 /PRNewswire/

PDL BioPharma Provides Fourth Quarter 2010 Revenue Guidance of $74 Million

INCLINE VILLAGE, Nev., Dec. 1, 2010 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2010 of

OrbusNeich Issues Statement on Boston Scientific's Unsuccessful Retaliatory Litigation Efforts in the Netherlands

Company Remains Confident In Patent Litigation Against Boston Scientific In the U.S.FT. LAUDERDALE, Fla. and HONG KONG, Dec. 1, 2010 /PRNewswire/ -- OrbusNeich Medical, Inc. ("OrbusNeich" or the

Delcath Names Bernard R. Tyrrell as Senior Vice President for North American Sales and Marketing

NEW YORK, Dec. 1, 2010 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) today announced the appointment of Bernard R. Tyrrell to the newly created position of Senior Vice President –

Frost & Sullivan Confers European Biopharmaceuticals Company of the Year Award on Debiopharm Group™

LONDON, Dec. 1, 2010 /PRNewswire/ -- The 2010 Frost & Sullivan Europe Company of the Year Award in Biopharmaceuticals is presented to Debiopharm Group™ (Debiopharm). (Logo:

Data at ASH, SABCS demonstrate commitment of Novartis R&D in advancing treatments for patients with cancer and rare diseases

- 24-month update on Phase III data comparing Tasigna® to Gleevec® in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseEAST HANOVER, N.J., Dec. 1, 2010 /PRNewswire/ -- With

Teva Announces $1 Billion Share Repurchase Program

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that its Board of Directors has authorized the Company to repurchase (including through one or more

Johnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010

Will further assess Korea Manufacturing Issues following Commencement of OfferNEW BRUNSWICK, N.J. and LEIDEN, the Netherlands, Nov. 30, 2010 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE:

Cordis Enters Distribution Agreement with Ostial Solutions for the Worldwide Distribution of the OSTIAL PRO Stent Position

BRIDGEWATER, N.J.--(BUSINESS WIRE)-- Cordis Corporation has entered into a distribution agreement with Ostial Solutions for the worldwide distribution of the OSTIAL PRO Stent Positioning System™. The

Omnicare Announces Offering of $500 Million of Convertible Senior Subordinated Notes Due 2025

COVINGTON, Ky.--(BUSINESS WIRE)-- Omnicare, Inc. (NYSE: OCR) (the “Company”) today announced that it intends to offer $500 million aggregate principal amount of its convertible senior subordinated

Micromet to Present at the 2010 Piper Jaffray Healthcare Conference

BETHESDA, Md.--(BUSINESS WIRE)-- Micromet, Inc. (NASDAQ: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer,

Analyst Available to Comment on the Potential Changes to Healthcare Reform After 2010 Election

Paula Wade, assistant director of managed market analysis with HealthLeaders-InterStudy, is available to discuss implications of healthcare reform as a result of the 2010 election. Additionally,

NewGene Ltd. Achieves Certification to Provide NimbleGen Sequence Capture Services in UK

PENZBERG, Germany--(BUSINESS WIRE)-- Roche NimbleGen (SWX:RO)(SWX:ROG)(Pink Sheets:RHHBY) announces that Newcastle-based genomic services provider NewGene Ltd. has officially become a Certified

Government patent box proposals 'transform' UK attractiveness for investment

GSK to invest £500m in manufacturing projects New £50m UK venture capital fund to be established New investment with academia on ‘green chemistry' GSK welcomes the publication